Arca
Skip to content
Tools
Tools

Cushing's disease

Drug research and approvals for cushing's disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 19 studies of cushing's disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, FDA has 4 approved and 0 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 19
  • Trials authorized in Canada: 8
  • FDA orphan approvals: 4
  • EU medicines: 1

Recruiting now

Newest posted first, of 19 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

Newest first; search them all in Canada trials
Jun 17, 2026A double-blind, randomised, 30-week placebo-controlled phase IV study to assess the efficacy and safety of osilodrostat in patients with hypertension caused by…Osilodrostat (LCI699)Recordati Rare DiseasesPending
Sep 18, 2023Continuation of an open-label, multi-center study to assess long term safety in Canadian patients with endogenous Cushing's syndrome who have completed prior…Osilodrostat (LCI669)Santé Québec- Centre Hospitalier De L’université De MontréalPending
Jun 4, 2019Glucocorticoid receptor antagonism in the treatment of Cushing syndrome (GRACE): a phase 3, double-blind, placebo-controlled, randomized-withdrawal study of…Relacorilant (CORT125134)Corcept TherapeuticsClosed
Jul 19, 2018An open-label, multi-center, roll-over study to assess long term safety in patients with endogenous Cushing's sundrome who have completed a prior…Osilodrostat (LCI699)Recordati Rare DiseasesClosed
May 2, 2017A phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of…Osilodrostat (LCI699)Novartis PharmaceuticalsClosed
Oct 8, 2014An open label study to assess the safety and efficacy of COR-003 (2s, 4r- ketoconazole) in the treatment of endogenous Cushing's syndromeKetoconazole (COR-003)Cortendo ABClosed
Jul 3, 2014A phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period…Osilodrostat (LCI699)Novartis PharmaceuticalsClosed
Apr 10, 2013An open label, multi-center pasireotide roll-over protocol for patients who have completed a previous novartis-sponsored pasireotide study and are judged by…Pasireotide (SOM230)Recordati Rare DiseasesClosed

FDA orphan designations

Approved first, then open designations, newest first
Apr 15, 2025IsturisaTreatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curativeRecordati Rare Diseases Inc.Approved
Mar 6, 2020IsturisaISTURISA is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery…Recordati Rare Diseases, IncApproved
Jun 29, 2018SigniforSIGNIFOR® LAR is indicated for the treatment of patients with Cushing’s disease for whom pituitary surgery is not an option or has not been…Novartis Pharmaceuticals CorporationApproved
Dec 14, 2012SigniforTreatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curativeNovartis Pharmaceuticals CorporationApproved

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Apr 24, 2012SigniforPasireotideRecordati Rare DiseasesEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.